Patient reported outcomes in gastroesophageal reflux disease: An overview of available measures

Quality of Life Research

Volumn 14, Issue 1, 2005, Pages 21-33

  Talley, Nicholas J ^a   Wiklund, Ingela ^b  

^a MAYO CLINIC   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Gastroesophageal reflux disease; Quality of life; Questionnaires

Indexed keywords

BARRETT ESOPHAGUS; EMOTION; EPIGASTRIC PAIN; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; REVIEW; RISK FACTOR; SELF REPORT; SYMPTOMATOLOGY; TREATMENT OUTCOME; VALIDATION PROCESS;

GASTROESOPHAGEAL REFLUX; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SWEDEN;

EID: 13844297660     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-004-0613-5     Document Type: Review

References (100)

1. Robinson, M. Dyspepsia: Challenges in diagnosis and selection of treatment. Clin Ther 2001; 23: 1130-1144.
2. Szarka LA, DeVault KR, Murray JA. Diagnosing gastroesophageal reflux disease. Mayo Clin Proc 2001; 76: 97-101.
3. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease: An overview. Am J Gastroenterol 2000; 95(Suppl. 8): S1-S3.
4. Avidan B, Sonnenberg A, Schnell, TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 1930-1936.
5. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002; 287: 1972-1981.
6. Richter JE. Peptic strictures of the esophagus. Gastroenterol Clin North Am 1999; 28: 875-891.
7. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: Prevalence, risk factors, impact and consulting - a population based study. Aliment Pharmacol Ther 2003; 17: 1115-1124.
8. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: Comparison of consulters and non-consulters. J R Coll Gen Pract 1989; 39: 495-498.
9. Kirtikumar J, Piterman L, McCall L. Gastroesophageal reflux and quality of life: Patients' knowledge, attitudes and perceptions. Aust Fam Physician 1999; 28(Suppl. 1): S15-S18.
10. Rush DR, Stelmach WJ, Young TI, et al. Clinical effectiveness and quality of life with ranitidine vs. placebo in gastroesophageal reflux patients: A clinical experience network (CEN) study. J Fam Pract 1995; 41: 126-136.
11. Sjoland H, Wiklund I, Caidahl K, Haglid M, Westberg S, Herlitz J. Improvement in quality of life and exercise capacity after coronary bypass surgery. Arch Intern Med 1996; 156: 265-271.
12. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456.
13. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999; 44(Suppl. 2): S1-S16.
14. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999; 72(2-3): 93-100.
15. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population. Ann Med 1995; 27: 67-70.
16. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
17. McDoughall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagitis: A 10 year follow up of its effect on patient symptomology and quality of life. Gut 1996; 38: 481-486.
18. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95: 788-792.
19. Vakil N, Ryden-Bergsten T, Bergenheim K. Systematic review: Patient-centred end points in economic evaluations of gastroesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1469-1480.
20. Wahlqvist P, Carlsson J, Stalhammar N, Wiklund I. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (wpai-gerd) - results from a cross sectional study. Value Health 2002; 5: 106-113.
21. The Pink Sheet, October 7th 2002: p. 31.
22. Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-esophageal reflux disease. Drugs 2003; 63: 2307-2316.
23. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labelling and promotion. Value Health 1999; 2: 113-127.
24. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient perspective into drug development and communication: An ad hoc task force report of the patient reported outcomes (PRO) harmonization meeting at the Food and Drug Administration, 16 February, 2001.
25. Wiklund I. Assessment of patient-reported outcomes in clinical trials: The example of health-related quality of life. Fundam Clin Pharmacol 2004; 18: 1-13.
26. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labelling and promotional claims in the United States. Qual Life Res 2000; 9: 887-900.
27. Santanello NC, Baker D, Cappelleri JC, et al. Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee Workshop, 1999. Value Health 2002; 5: 14-25.
28. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: The example of health-related quality of life - a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002; 36: 209-238.
29. Yorulmaz I, Ozlugedik S, Kucuk B. Gastroesophageal reflux disease: Symptoms vs. pH monitoring results. Otolaryngol Head Neck Surg 2003; 129(5): 582-586.
30. DiBaise JK, Lof J, Quigley EMM. Can symptoms predict esophageal motor function or acid exposure in gastroesophageal reflux disease? J Clin Gastroenterol 2001; 32: 128-132.
31. Gralnek IM. Diagnosis and management of gastroesophageal reflux disease in the primary care setting: Can health-related quality of life play a role? Am J Gastroenterol 2001; 96(Suppl. 8): S54-S56.
32. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med 1993; 118: 622-629.
33. Patrick DL, Reyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 5: 217-232.
34. Shumaker SA, Berzon RA. The International Assessment of HRQL. Theory, Translations, Measurement and Analysis. Oxford: Rapid Communications, 1995.
35. Guyatt GH, Feeny D, Patrick DL. Issues in quality of life measurement in clinical trials. Control Clin Trials 1991; 12(Suppl. 4): 81S-90S.
36. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston, The Health Institute. New England Medical Centre, 1993.
37. Bergner M, Bobbitt RA, Carter WB, Gibson BS. The sickness impact profile: Development and final revision of a health status measure. Med Care 1981; 19: 787-796.
38. Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wender NK, Mattson ME, Furberg CD, Elinson J (eds), Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: le Jacq, 1984: 170-183.
39. Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998; (Suppl. 583): 41-49.
40. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75-83.
41. Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease. Relationship between the health-related quality of life score and psychologic parameters. Am Surg 1998; 7: 649-653.
42. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a Diagnostic Questionnaire for Gastroesophageal Reflux Disease. Am J Gastroenterol 2001; 96: 52-57.
43. Wiklund I, Dimenas E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials 1990; 11: 169-179.
44. Guyatt GH, Veldheuyzen van Zanten SJO, Feeny DH, Patrick DL. Measuring quality of life in clinical trials: A taxonomy and review. Can Med Assoc J 1989; 140: 1441-1448.
45. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27: S217-S232.
46. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998; 2(14) i-iv, 1-74.
47. Kirschner B, Guyatt G. A methodological framework for assessing health indices. J Chron Dis 1985; 38: 27-36.
48. Maunder RG, Cohen Z, McLeod RS, Greenberg GL. Effect of intervention in inflammatory bowel disease on health related quality of life: A critical review. Dis Colon Rectum 1995; 38: 1147-1161.
49. Gill T, Feinstein AR. A critical appraisal of the quality of quality of life instruments. JAMA 1994; 272: 619-626.
50. Guyatt G, Cook D. Health status, quality of life and the individual. JAMA 1994; 272: 630-631.
51. Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurements in clinical trials. In: Staquet M, Hays R, Fayers P (eds), Quality of Life Assessment in Clinical Trials. New York: Oxford University Press, 1998: 169-182.
52. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.
53. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health related quality of life: The remarkable university of half a standard deviation. Med Care 2003; 41: 582-592.
54. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 469-478.
55. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-226.
56. Samsa G, Edelman D, Rothman ML, Willimas RG, Liscomb J, Machtar D. Determining clinically important differences in health status measures. A general approach with illustration to the health utilities index mark II. Pharmacoeconomics 1999; 15: 141-155.
57. Sprangers MAG, Moinpur CM, Moynihan TJ, Patrick DL, Reviki DA. Assessing meaningful change in quality of life over time: A user's guide for clinicians. Mayo Clin Proc 2002; 77: 561-571.
58. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy negative heartburn: Reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998-2004.
59. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining the minimal important difference in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87.
60. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
61. Raczek AE, Ware JE, Bjorner JB, et al. Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: Results from the IQOLA Project. J Clin Epidemiol 1998; 51: 1203-1214.
62. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-1487.
63. Fayers PM, Machin D. Quality of Life. Assessment, Analysis and Interpretation. Chichester: John Wiley & Sons Ltd, 2000.
64. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Academic Press, 1977.
65. Cella D, Bullinger M, Scott C, Barofsky I. Group vs. individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc 2002; 77: 384-392.
66. Baker DW, Hays RD, Brook RH. Understanding changes in health status: Is the floor phenomenon merely the last step of the staircase? Med Care 1997; 35: 1-15.
67. Liang MH. Longitudinal construct validity: Establishment of clinical meaning in patient evaluative instruments. Med Care 2000; 38(Suppl 9): I184-I190.
68. Lydick E. Approaches to the interpretation of quality of life scales. Med Care 2000; 38(Suppl. 9): I180-I183.
69. Stucki G, Liang MH, Fossel AH, Katz JN. Relative responsiveness of condition specific and generic health status measures in degenerative lumbar spinal stenosis. J Clin Epidemiol 1995; 48: 1369-1378.
70. Junghard O, Wiklund I. What is a minimal important difference in patient-reported outcomes in the treatment of reflux disease? Clin Ther 2003; 25(Suppl. D): D41-D42, A28.
71. Wiklund I, Junghard O. What is clinically relevant change in patient-reported outcomes in the treatment of reflux disease? Clin Ther 2003; 25 (Suppl. D): D47-D48, A33.
72. Chal KL, Stacey JH, Sacks GE. The effect of ranitidine on symptom relief and quality of life of patients with gastrooesophageal reflux disease. Br J Clin Pract 1995; 49: 73-77.
73. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well being and gastrointestinal symptoms among patients referred to endoscopy among suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-1052.
74. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. The relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scan J Gastroenterol Suppl 1996; 221: 8-13.
75. Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997; 11: 73-77.
76. Revicki DA, Sorenson S, Maton PN, Orlando, JC. Health related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 284-291.
77. Revicki DA, Leidy NK, Howland L. Evaluating the psychometric characteristics of the psychological general well-being index with a new response scale. Qual Life Res 1996; 5: 417-423.
78. Revicki DA, Allen H, Beungay K, Williams GH, Weinstein MC. Responsiveness and calibration of the general well-being adjustment scale in patients with hypertension. J Clin Epidemiol 1994; 47: 1333-1342.
79. Mayo E. The Human Problems of an Industrial Civilization. New York: MacMillan, 1933: chap. 3.
80. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129-134.
81. Yacavone RF, Locke GR, Provenzale DT, Eisen GM. Quality of life measurement in gastroenterology: What is available? Am J Gastroenterol 2001; 96: 285-297.
82. Shaw M, Dent J, Beebe T, et al. The Reflux Disease Questionnaire: A New Measure to Assess Treatment Response in Clinical Trials, in press.
83. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. Br J Surg 1995; 82: 216-122.
84. Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 315-324.
85. Prasad M, Rentz AM, Revicki DA. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life. Pharmacoeconomics 2003: 21(11): 769-790.
86. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 539-547.
87. Eloubeidi MA, Provenzale D. Health related quality of life and severity of symptoms in patients with Barrett's esophagus and gastrointestinal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 2000; 95: 1881-1887.
88. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444-454.
89. Kulig M, Leodolter AL, Schulte E, et al. Quality of life in patients with gastroesophageal reflux disease. Gastroenterology 2002; 122(4 Suppl. 1): A-197.
90. Talley NJ, Junghard O, Wiklund IK. Why do patients with gastroesophageal reflux disease (GERD) have a poor health-related quality of life (HRQL)? Gastroenterology 2001; 120(Suppl. A): 423.
91. Lauritsen K, Junghard O, Eklund S, Wiklund I. The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Gastroenterology 2002; 122(4 Suppl. 1): A-200.
92. Glise H, Wiklund I. Health-related quality of life and gastrointestinal disease. J Gastroenterol Hepatol 2002; 17(Suppl.): S72-S84.
93. Young TL, Kirchdoerfer LJ, Osterhaus, JT. A development and validation process for a disease specific quality of life instrument. Drug Information J 1996; 30: 185-193.
94. Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality of life measures for selected gastrointestinal disease studies: A review and synthesis of the literature. Pharmacoeconomics 2001; 19: 349-363.
95. Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584-589.
96. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989; 262: 907-913.
97. Wiklund I, Talley N. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3(3): 341-350.
98. Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-2253.
99. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
100. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-199.